Artelo Biosciences (Artelo Biosciences) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Artelo Biosciences's Free Cash Flow for the three months ended in Mar. 2024 was $-2.94 Mil. Artelo Biosciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Artelo Biosciences's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Artelo Biosciences's current FCF Yield % is 2.89%.

The historical rank and industry rank for Artelo Biosciences's FCF Margin % or its related term are showing as below:

ARTLW's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.31
* Ranked among companies with meaningful FCF Margin % only.

Artelo Biosciences FCF Margin % Historical Data

The historical data trend for Artelo Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences FCF Margin % Chart

Artelo Biosciences Annual Data

Trend

Aug14

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Artelo Biosciences Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Artelo Biosciences's FCF Margin %

For the Biotechnology subindustry, Artelo Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Artelo Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's FCF Margin % falls into.

Artelo Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Artelo Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.207	/	0
	=	%

Artelo Biosciences's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.942	/	0
	=	%

Artelo Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Artelo Biosciences (Artelo Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ARTL:USA

Address

505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075

Website

https://www.artelobio.com

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.